Next Article in Journal
Distribution of Porcine Cytomegalovirus in Infected Donor Pigs and in Baboon Recipients of Pig Heart Transplantation
Next Article in Special Issue
1st German Phage Symposium—Conference Report
Previous Article in Journal
All-Round Manipulation of the Actin Cytoskeleton by HIV
Previous Article in Special Issue
Characterization of vB_SauM-fRuSau02, a Twort-Like Bacteriophage Isolated from a Therapeutic Phage Cocktail
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessCommunication
Viruses 2018, 10(2), 64;

The Magistral Phage

Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital, Bruynstraat 1, 1120 Brussel, Belgium
Bacterial Diseases, Unit Antibiotic Resistance, Scientific Institute of Public Health, Rue Engelandstraat 642, 1180 Brussel, Belgium
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, O&N2, Herestraat 49, Box 521, 3000 Leuven, Belgium
Federal Agency for Medicines and Health Products, Place Victor Horta 40/40, 1060 Brussels, Belgium
Culture In Vivo ASBL, rue du Progrès, 4, boîte 7, 1400 Nivelles, Belgium
Author to whom correspondence should be addressed.
Received: 15 January 2018 / Revised: 2 February 2018 / Accepted: 3 February 2018 / Published: 6 February 2018
(This article belongs to the Special Issue Hurdles for Phage Therapy (PT) to Become a Reality)
Full-Text   |   PDF [348 KB, uploaded 8 February 2018]   |  


Since time immemorial, phages—the viral parasites of bacteria—have been protecting Earth’s biosphere against bacterial overgrowth. Today, phages could help address the antibiotic resistance crisis that affects all of society. The greatest hurdle to the introduction of phage therapy in Western medicine is the lack of an appropriate legal and regulatory framework. Belgium is now implementing a pragmatic phage therapy framework that centers on the magistral preparation (compounding pharmacy in the US) of tailor-made phage medicines. View Full-Text
Keywords: antibiotic; antimicrobial resistance; magistral preparation; compounding pharmacy; phage therapy; regulatory framework; personalized medicine antibiotic; antimicrobial resistance; magistral preparation; compounding pharmacy; phage therapy; regulatory framework; personalized medicine

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Pirnay, J.-P.; Verbeken, G.; Ceyssens, P.-J.; Huys, I.; De Vos, D.; Ameloot, C.; Fauconnier, A. The Magistral Phage. Viruses 2018, 10, 64.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top